Literature DB >> 9538995

Diabetes and risk of adverse events with calcium antagonists.

M Pahor, S B Kritchevsky, G Zuccala, J M Guralnik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9538995     DOI： 10.2337/diacare.21.1.193

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  6 in total

Review 1.  Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies.

Authors:  M Pahor; C D Furberg
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

Review 2.  Antihypertensive drugs and diabetic nephropathy.

Authors:  P S Mehler; R W Schrier
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

3.  Controversies surrounding the treatment of the hypertensive patient with diabetes.

Authors:  L M Prisant; R J Louard
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

Review 4.  Treatment of diabetic patients with hypertension.

Authors:  W H Birkenhäger; J A Staessen
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

Review 5.  The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension.

Authors:  P Sleight
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

6.  Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J).

Authors:  Ryuzo Kawamori; Hiroyuki Daida; Yasushi Tanaka; Katsumi Miyauchi; Akira Kitagawa; Dobun Hayashi; Junji Kishimoto; Shunya Ikeda; Yutaka Imai; Tsutomu Yamazaki
Journal:  BMC Cardiovasc Disord       Date:  2006-10-09       Impact factor: 2.298
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.